Novartis AG plans to seek regulatory approval within 18 months for a pioneering tablet containing an embedded microchip, bringing the concept of "smart-pill" technology a step closer.
The initial program will use one of the Swiss firm's established drugs taken by transplant patients to avoid organ rejection. But Trevor Mundel, global head of development, believes the concept can be applied to many other pills.
"We are taking forward this transplant drug with a chip and we hope within the next 18 months to have something that we will be able to submit to the regulators, at least in Europe," Mundel told the Reuters Health Summit in New York.
"I see the promise as going much beyond that," he added.
Novartis agreed in January to spend $24 million to secure access to chip-in-a-pill technology developed by privately owned Proteus Biomedical of Redwood City, California, putting it ahead of rivals.
The biotech start-up's ingestible chips are activated by stomach acid and send information to a small patch worn on the patient's skin, which can transmit data to a smartphone or send it over the Internet to a doctor.
Mundel said the initial project was focused on ensuring that patients took drugs at the right time and got the dose they needed -- a key issue for people after kidney and other transplant operations, when treatment frequently needs adjustment.
Longer-term, he hopes to expand the "smart pill" concept to other types of medicine and use the wealth of biometric information the Proteus chip can collect, from heart rate and temperature to body movement, to check that drugs are working properly.
Read Full Article
Secretive Executive Order Establishes Big Brother Health Bureaucracy
Big Pharma Makes Another Killing